CHEMIOTERAPIA CON FUDR IN INFUSIONE CONTINUA NEL TRATTAMENTO DEL CARCINOMA RENALE METASTATICO O IN STADIO AVANZATO

Translated title of the contribution: Continuous infusion chemotherapy with FUDR in the treatment of advanced metastatic renal carcinoma

A. Del Nero, A. Mandressi, G. Zanetti, A. Trinchieri, E. Patelli, G. L. Taverna, E. Austoni

Research output: Contribution to journalArticlepeer-review

Abstract

The cases of metastatic renal cell carcinoma and 14 cases of advanced renal cell carcinoma were treated with continuous circadian venous infusion of 5-Fluoro 2-Deoxyuridine (FUDR). The drug was delivered by a Medtronic Synchromed implantable pump in 14 day cycles alternating within 14 day intervals of physiologic saline infusion. Of the patients observed for at least 18 months (range: 18-46 months, median: 32.4) in Group A, 5 showed progress, 3 stable disease (range: 9-20 months), 2 partial response (range: 9-29 months), while in Group B, only 1 case showed progression. Continuous circadian central venous infusion of FUDR is minimally toxic. FUDR may be delivered safely and conveniently in this way for long spans. Therapy is administered entirely in an out-patient setting, and associated with a normal quality of life.

Translated title of the contributionContinuous infusion chemotherapy with FUDR in the treatment of advanced metastatic renal carcinoma
Original languageItalian
Pages (from-to)83-84
Number of pages2
JournalActa Urologica Italica
Volume6
Issue numberSUPPL. 4
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Continuous infusion chemotherapy with FUDR in the treatment of advanced metastatic renal carcinoma'. Together they form a unique fingerprint.

Cite this